Docosahexaenoic acid-rich fish oil supplementation reduces kinase associated with insulin resistance in overweight and obese midlife adults

Rohith N. Thota; Jessica I. Rosato; Tracy L. Burrows; Cintia B. Dias; Kylie A. Abbott; Ralph N. Martins; Manohar L. Garg

doi:10.3390/nu12061612

Docosahexaenoic acid-rich fish oil supplementation reduces kinase associated with insulin resistance in overweight and obese midlife adults

Rohith N. Thota, Jessica I. Rosato, Tracy L. Burrows, Cintia B. Dias, Kylie A. Abbott, Ralph N. Martins, Manohar L. Garg

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

36 Downloads (Pure)

Abstract

Targeting kinases linked to insulin resistance (IR) and inflammation may help in reducing the risk of type 2 diabetes (T2D) and Alzheimer’s disease (AD) in its early stages. This study aimed to determine whether DHA-rich fish oil supplementation reduces glycogen synthase kinase (GSK-3), which is linked to both IR and AD. Baseline and post-intervention plasma samples from 58 adults with abdominal obesity (Age: 51.7 ± 1.7 years, BMI: 31.9 ± 0.8 kg/m²) were analysed for outcome measures. Participants were allocated to 2 g DHA-rich fish oil capsules (860 mg DHA + 120 mg EPA) (n = 31) or placebo capsules (n = 27) per day for 12 weeks. Compared to placebo, DHA-rich fish oil significantly reduced GSK-3β by -2.3 ± 0.3 ng/mL. An inverse correlation (p < 0.05) was found between baseline insulin and IR and their changes following intervention only in participants with C-reactive protein levels higher than 2.4 mg/L. DHA-rich fish oil reduces GSK-3 and IR, suggesting a potential role of long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) in ameliorating AD risk.

Original language	English
Article number	1612
Pages (from-to)	1-13
Number of pages	13
Journal	Nutrients
Volume	12
Issue number	6
DOIs	https://doi.org/10.3390/nu12061612
Publication status	Published - 30 May 2020

Bibliographical note

Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

long-chain omega-3 polyunsaturated fatty acids
docosahexaenoic acid
insulin resistance
obesity
Alzheimer’s disease
glycogen synthase kinase-3

Access to Document

10.3390/nu12061612

Publisher version (open access)Final published version, 1.31 MBLicence: CC BY

Cite this

@article{93af49bc575845b298ef53d50c758d9a,

title = "Docosahexaenoic acid-rich fish oil supplementation reduces kinase associated with insulin resistance in overweight and obese midlife adults",

abstract = "Targeting kinases linked to insulin resistance (IR) and inflammation may help in reducing the risk of type 2 diabetes (T2D) and Alzheimer{\textquoteright}s disease (AD) in its early stages. This study aimed to determine whether DHA-rich fish oil supplementation reduces glycogen synthase kinase (GSK-3), which is linked to both IR and AD. Baseline and post-intervention plasma samples from 58 adults with abdominal obesity (Age: 51.7 ± 1.7 years, BMI: 31.9 ± 0.8 kg/m2) were analysed for outcome measures. Participants were allocated to 2 g DHA-rich fish oil capsules (860 mg DHA + 120 mg EPA) (n = 31) or placebo capsules (n = 27) per day for 12 weeks. Compared to placebo, DHA-rich fish oil significantly reduced GSK-3β by -2.3 ± 0.3 ng/mL. An inverse correlation (p < 0.05) was found between baseline insulin and IR and their changes following intervention only in participants with C-reactive protein levels higher than 2.4 mg/L. DHA-rich fish oil reduces GSK-3 and IR, suggesting a potential role of long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) in ameliorating AD risk.",

keywords = "long-chain omega-3 polyunsaturated fatty acids, docosahexaenoic acid, insulin resistance, obesity, Alzheimer{\textquoteright}s disease, glycogen synthase kinase-3",

author = "Thota, {Rohith N.} and Rosato, {Jessica I.} and Burrows, {Tracy L.} and Dias, {Cintia B.} and Abbott, {Kylie A.} and Martins, {Ralph N.} and Garg, {Manohar L.}",

note = "Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2020",

month = may,

day = "30",

doi = "10.3390/nu12061612",

language = "English",

volume = "12",

pages = "1--13",

journal = "Nutrients",

issn = "2072-6643",

publisher = "MDPI",

number = "6",

}

TY - JOUR

T1 - Docosahexaenoic acid-rich fish oil supplementation reduces kinase associated with insulin resistance in overweight and obese midlife adults

AU - Thota, Rohith N.

AU - Rosato, Jessica I.

AU - Burrows, Tracy L.

AU - Dias, Cintia B.

AU - Abbott, Kylie A.

AU - Martins, Ralph N.

AU - Garg, Manohar L.

N1 - Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2020/5/30

Y1 - 2020/5/30

N2 - Targeting kinases linked to insulin resistance (IR) and inflammation may help in reducing the risk of type 2 diabetes (T2D) and Alzheimer’s disease (AD) in its early stages. This study aimed to determine whether DHA-rich fish oil supplementation reduces glycogen synthase kinase (GSK-3), which is linked to both IR and AD. Baseline and post-intervention plasma samples from 58 adults with abdominal obesity (Age: 51.7 ± 1.7 years, BMI: 31.9 ± 0.8 kg/m2) were analysed for outcome measures. Participants were allocated to 2 g DHA-rich fish oil capsules (860 mg DHA + 120 mg EPA) (n = 31) or placebo capsules (n = 27) per day for 12 weeks. Compared to placebo, DHA-rich fish oil significantly reduced GSK-3β by -2.3 ± 0.3 ng/mL. An inverse correlation (p < 0.05) was found between baseline insulin and IR and their changes following intervention only in participants with C-reactive protein levels higher than 2.4 mg/L. DHA-rich fish oil reduces GSK-3 and IR, suggesting a potential role of long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) in ameliorating AD risk.

AB - Targeting kinases linked to insulin resistance (IR) and inflammation may help in reducing the risk of type 2 diabetes (T2D) and Alzheimer’s disease (AD) in its early stages. This study aimed to determine whether DHA-rich fish oil supplementation reduces glycogen synthase kinase (GSK-3), which is linked to both IR and AD. Baseline and post-intervention plasma samples from 58 adults with abdominal obesity (Age: 51.7 ± 1.7 years, BMI: 31.9 ± 0.8 kg/m2) were analysed for outcome measures. Participants were allocated to 2 g DHA-rich fish oil capsules (860 mg DHA + 120 mg EPA) (n = 31) or placebo capsules (n = 27) per day for 12 weeks. Compared to placebo, DHA-rich fish oil significantly reduced GSK-3β by -2.3 ± 0.3 ng/mL. An inverse correlation (p < 0.05) was found between baseline insulin and IR and their changes following intervention only in participants with C-reactive protein levels higher than 2.4 mg/L. DHA-rich fish oil reduces GSK-3 and IR, suggesting a potential role of long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) in ameliorating AD risk.

KW - long-chain omega-3 polyunsaturated fatty acids

KW - docosahexaenoic acid

KW - insulin resistance

KW - obesity

KW - Alzheimer’s disease

KW - glycogen synthase kinase-3

UR - http://www.scopus.com/inward/record.url?scp=85085909106&partnerID=8YFLogxK

U2 - 10.3390/nu12061612

DO - 10.3390/nu12061612

M3 - Article

C2 - 32486256

SN - 2072-6643

VL - 12

SP - 1

EP - 13

JO - Nutrients

JF - Nutrients

IS - 6

M1 - 1612

ER -

Docosahexaenoic acid-rich fish oil supplementation reduces kinase associated with insulin resistance in overweight and obese midlife adults

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this